In the News

Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:

Featured Article

Here’s when your weight loss will plateau, according to science

CNN
Monday, April 22, 2024

Whether you’re shedding pounds with the help of effective new medicines, slimming down after weight loss surgery or cutting calories and adding exercise, there will come a day when the numbers on the scale stop going down, and you hit the dreaded weight loss plateau.

In a recent study, Kevin Hall, a researcher at the National Institutes of Health who specializes in measuring metabolism and weight change, looked at when weight loss typically stops depending on the method people were using to drop pounds. He broke down the plateau into mathematical models using data from high-quality clinical trials of different ways to lose weight to understand why people stop losing when they do. The study published Monday in the journal Obesity.

Closing in on risk factors for cerebral palsy and infant death

Scientists from NIH and Australia investigate risk factors that contribute to cerebral palsy and early infant death

Karin B. Nelson, M.D., scientist emeritus at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and her colleagues from the University of Sydney, the University of Western Australia and Sydney Adventist Hospital in Australia examined the degree to which four specific risk factors contributed to cerebral palsy and young infant death. The risk factors were asphyxial birth events (incidences during labor and delivery that had the potential to interfere with oxygen getting to the newborn’s brain), inflammation (signs of infection), birth defects, and poor fetal growth (low birth weight plus some other factors related to expected size).

Single gene change increases mouse lifespan by 20 percent

NIH intramural study also shows that individual organs are affected differently

By lowering the expression of a single gene, researchers at the National Institutes of Health have extended the average lifespan of a group of mice by about 20 percent — the equivalent of raising the average human lifespan by 16 years, from 79 to 95. The research team targeted a gene called mTOR, which is involved in metabolism and energy balance, and may be connected with the increased lifespan associated with caloric restriction.

Investigational oral regimen for hepatitis C shows promise in NIH trial

Side effects minimized with combination therapy in hard-to-treat patients

In a study of an all-oral drug regimen, a majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin. The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) and the NIH Clinical Center, parts of the National Institutes of Health, led the Phase II trial.

NIH study finds chronic alcohol use shifts brain’s control of behavior

Chronic alcohol exposure leads to brain adaptations that shift behavior control away from an area of the brain involved in complex decision-making and toward a region associated with habit formation, according to a new study conducted in mice by scientists at the National Institutes of Health.

3-D images show flame retardants can mimic estrogens in NIH study

By determining the three-dimensional structure of proteins at the atomic level, researchers at the National Institutes of Health have discovered how some commonly used flame retardants, called brominated flame retardants (BFRs), can mimic estrogen hormones and possibly disrupt the body’s endocrine system. BFRs are chemicals added or applied to materials to slow or prevent the start or growth of fire.

Endocannabinoids trigger inflammation that leads to diabetes

Researchers at the National Institutes of Health have clarified in rodent and test tube experiments the role that inflammation plays in type 2 diabetes, and revealed a possible molecular target for treating the disease. The researchers say some natural messenger chemicals in the body are involved in an inflammatory chain that can kill cells in the pancreas, which produces insulin.

Investigational malaria vaccine found safe and protective

NIH vaccine researchers publish results of early-stage clinical trial

An investigational malaria vaccine has been found to be safe, to generate an immune system response, and to offer protection against malaria infection in healthy adults, according to the results of an early-stage clinical trial.

NIH scientists visualize how cancer chromosome abnormalities form in living cells

For the first time, scientists have directly observed events that lead to the formation of a chromosome abnormality that is often found in cancer cells. The abnormality, called a translocation, occurs when part of a chromosome breaks off and becomes attached to another chromosome. The results of this study, conducted by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appeared Aug. 9, 2013, in the journal Science.

Removing a protein enhances defense against bacteria in CGD mice

NIH study also suggests an alternative, adjunct approach to drug-resistant staph infections

Deletion of a protein in white blood cells improves their ability to fight the bacteria staphylococcus aureus and possibly other infections in mice with chronic granulomatous disease (CGD), according to a National Institutes of Health study. CGD, a genetic disorder also found in people, is marked by recurrent, life-threatening infections.

NIH researchers find diabetes drug extends health and lifespan in mice

Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when started at middle age, reports an international team of scientists led by researchers at the National Institute on Aging (NIA), part of the National Institutes Health. The study, which tested two doses of the drug in the male mice, found the higher dose to be toxic in the animals. Scientists emphasized that considerably more research is needed before the implications of metformin for healthy aging are known for humans.

Continue Exploring the IRP

This page was last updated on Monday, April 22, 2024